Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
The global Benign Prostatic Hyperplasia Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tamsulosin Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Benign Prostatic Hyperplasia Drugs include Sanofi, Boehringer Ingelheim, Maithili Life Sciences, DM Pharma, Teva Pharmaceuticals, Mylan, Zydus Pharmaceuticals, Wockhardt and Sun Pharmaceutical, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Drugs. This report contains market size and forecasts of Benign Prostatic Hyperplasia Drugs in global, including the following market information:
Global Benign Prostatic Hyperplasia Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Benign Prostatic Hyperplasia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Benign Prostatic Hyperplasia Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Benign Prostatic Hyperplasia Drugs Market Segment Percentages, by Type, 2022 (%)
Tamsulosin
Finasteride
Terazosin
Other
Global Benign Prostatic Hyperplasia Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Benign Prostatic Hyperplasia Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Other
Global Benign Prostatic Hyperplasia Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Benign Prostatic Hyperplasia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Benign Prostatic Hyperplasia Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Benign Prostatic Hyperplasia Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Boehringer Ingelheim
Maithili Life Sciences
DM Pharma
Teva Pharmaceuticals
Mylan
Zydus Pharmaceuticals
Wockhardt
Sun Pharmaceutical
Glenmark Pharmaceuticals Ltd.
TRB Pharma S.A.
Kunming Jida Pharmaceutical Co., Ltd.
Medzeel Lifescience
Wellona Pharma
Niksan Pharmaceutical
Lunan Pharmaceutical Group Corporation
Zhejiang Xianju Pharmaceutical Co.,Ltd.
Hunan Jiudian Pharmaceutical Co.,Ltd.
Chengdu Brilliant Pharmaceutical Co., Ltd.
Guangdong Eashu Pharmaceutical Co.,Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Benign Prostatic Hyperplasia Drugs, market overview.
Chapter 2: Global Benign Prostatic Hyperplasia Drugs market size in revenue.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Benign Prostatic Hyperplasia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Benign Prostatic Hyperplasia Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Benign Prostatic Hyperplasia Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Benign Prostatic Hyperplasia Drugs Overall Market Size
2.1 Global Benign Prostatic Hyperplasia Drugs Market Size: 2022 VS 2029
2.2 Global Benign Prostatic Hyperplasia Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Benign Prostatic Hyperplasia Drugs Players in Global Market
3.2 Top Global Benign Prostatic Hyperplasia Drugs Companies Ranked by Revenue
3.3 Global Benign Prostatic Hyperplasia Drugs Revenue by Companies
3.4 Top 3 and Top 5 Benign Prostatic Hyperplasia Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Benign Prostatic Hyperplasia Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Benign Prostatic Hyperplasia Drugs Players in Global Market
3.6.1 List of Global Tier 1 Benign Prostatic Hyperplasia Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Benign Prostatic Hyperplasia Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Benign Prostatic Hyperplasia Drugs Market Size Markets, 2022 & 2029
4.1.2 Tamsulosin
4.1.3 Finasteride
4.1.4 Terazosin
4.1.5 Other
4.2 By Type - Global Benign Prostatic Hyperplasia Drugs Revenue & Forecasts
4.2.1 By Type - Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2023
4.2.2 By Type - Global Benign Prostatic Hyperplasia Drugs Revenue, 2024-2029
4.2.3 By Type - Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Benign Prostatic Hyperplasia Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Benign Prostatic Hyperplasia Drugs Revenue & Forecasts
5.2.1 By Application - Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2023
5.2.2 By Application - Global Benign Prostatic Hyperplasia Drugs Revenue, 2024-2029
5.2.3 By Application - Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Benign Prostatic Hyperplasia Drugs Market Size, 2022 & 2029
6.2 By Region - Global Benign Prostatic Hyperplasia Drugs Revenue & Forecasts
6.2.1 By Region - Global Benign Prostatic Hyperplasia Drugs Revenue, 2018-2023
6.2.2 By Region - Global Benign Prostatic Hyperplasia Drugs Revenue, 2024-2029
6.2.3 By Region - Global Benign Prostatic Hyperplasia Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6.3.2 US Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.3.3 Canada Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.3.4 Mexico Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6.4.2 Germany Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.3 France Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.4 U.K. Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.5 Italy Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.6 Russia Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.4.8 Benelux Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6.5.2 China Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.5.3 Japan Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.5.4 South Korea Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.5.6 India Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6.6.2 Brazil Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.6.3 Argentina Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Benign Prostatic Hyperplasia Drugs Revenue, 2018-2029
6.7.2 Turkey Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.7.3 Israel Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
6.7.5 UAE Benign Prostatic Hyperplasia Drugs Market Size, 2018-2029
7 Benign Prostatic Hyperplasia Drugs Companies Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.1.4 Sanofi Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Summary
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.2.4 Boehringer Ingelheim Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.2.5 Boehringer Ingelheim Key News & Latest Developments
7.3 Maithili Life Sciences
7.3.1 Maithili Life Sciences Company Summary
7.3.2 Maithili Life Sciences Business Overview
7.3.3 Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.3.4 Maithili Life Sciences Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.3.5 Maithili Life Sciences Key News & Latest Developments
7.4 DM Pharma
7.4.1 DM Pharma Company Summary
7.4.2 DM Pharma Business Overview
7.4.3 DM Pharma Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.4.4 DM Pharma Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.4.5 DM Pharma Key News & Latest Developments
7.5 Teva Pharmaceuticals
7.5.1 Teva Pharmaceuticals Company Summary
7.5.2 Teva Pharmaceuticals Business Overview
7.5.3 Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.5.4 Teva Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.5.5 Teva Pharmaceuticals Key News & Latest Developments
7.6 Mylan
7.6.1 Mylan Company Summary
7.6.2 Mylan Business Overview
7.6.3 Mylan Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.6.4 Mylan Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.6.5 Mylan Key News & Latest Developments
7.7 Zydus Pharmaceuticals
7.7.1 Zydus Pharmaceuticals Company Summary
7.7.2 Zydus Pharmaceuticals Business Overview
7.7.3 Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.7.4 Zydus Pharmaceuticals Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.7.5 Zydus Pharmaceuticals Key News & Latest Developments
7.8 Wockhardt
7.8.1 Wockhardt Company Summary
7.8.2 Wockhardt Business Overview
7.8.3 Wockhardt Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.8.4 Wockhardt Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.8.5 Wockhardt Key News & Latest Developments
7.9 Sun Pharmaceutical
7.9.1 Sun Pharmaceutical Company Summary
7.9.2 Sun Pharmaceutical Business Overview
7.9.3 Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.9.4 Sun Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.9.5 Sun Pharmaceutical Key News & Latest Developments
7.10 Glenmark Pharmaceuticals Ltd.
7.10.1 Glenmark Pharmaceuticals Ltd. Company Summary
7.10.2 Glenmark Pharmaceuticals Ltd. Business Overview
7.10.3 Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.10.4 Glenmark Pharmaceuticals Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.10.5 Glenmark Pharmaceuticals Ltd. Key News & Latest Developments
7.11 TRB Pharma S.A.
7.11.1 TRB Pharma S.A. Company Summary
7.11.2 TRB Pharma S.A. Business Overview
7.11.3 TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.11.4 TRB Pharma S.A. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.11.5 TRB Pharma S.A. Key News & Latest Developments
7.12 Kunming Jida Pharmaceutical Co., Ltd.
7.12.1 Kunming Jida Pharmaceutical Co., Ltd. Company Summary
7.12.2 Kunming Jida Pharmaceutical Co., Ltd. Business Overview
7.12.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.12.4 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.12.5 Kunming Jida Pharmaceutical Co., Ltd. Key News & Latest Developments
7.13 Medzeel Lifescience
7.13.1 Medzeel Lifescience Company Summary
7.13.2 Medzeel Lifescience Business Overview
7.13.3 Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.13.4 Medzeel Lifescience Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.13.5 Medzeel Lifescience Key News & Latest Developments
7.14 Wellona Pharma
7.14.1 Wellona Pharma Company Summary
7.14.2 Wellona Pharma Business Overview
7.14.3 Wellona Pharma Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.14.4 Wellona Pharma Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.14.5 Wellona Pharma Key News & Latest Developments
7.15 Niksan Pharmaceutical
7.15.1 Niksan Pharmaceutical Company Summary
7.15.2 Niksan Pharmaceutical Business Overview
7.15.3 Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.15.4 Niksan Pharmaceutical Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.15.5 Niksan Pharmaceutical Key News & Latest Developments
7.16 Lunan Pharmaceutical Group Corporation
7.16.1 Lunan Pharmaceutical Group Corporation Company Summary
7.16.2 Lunan Pharmaceutical Group Corporation Business Overview
7.16.3 Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.16.4 Lunan Pharmaceutical Group Corporation Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.16.5 Lunan Pharmaceutical Group Corporation Key News & Latest Developments
7.17 Zhejiang Xianju Pharmaceutical Co.,Ltd.
7.17.1 Zhejiang Xianju Pharmaceutical Co.,Ltd. Company Summary
7.17.2 Zhejiang Xianju Pharmaceutical Co.,Ltd. Business Overview
7.17.3 Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.17.4 Zhejiang Xianju Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.17.5 Zhejiang Xianju Pharmaceutical Co.,Ltd. Key News & Latest Developments
7.18 Hunan Jiudian Pharmaceutical Co.,Ltd.
7.18.1 Hunan Jiudian Pharmaceutical Co.,Ltd. Company Summary
7.18.2 Hunan Jiudian Pharmaceutical Co.,Ltd. Business Overview
7.18.3 Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.18.4 Hunan Jiudian Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.18.5 Hunan Jiudian Pharmaceutical Co.,Ltd. Key News & Latest Developments
7.19 Chengdu Brilliant Pharmaceutical Co., Ltd.
7.19.1 Chengdu Brilliant Pharmaceutical Co., Ltd. Company Summary
7.19.2 Chengdu Brilliant Pharmaceutical Co., Ltd. Business Overview
7.19.3 Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.19.4 Chengdu Brilliant Pharmaceutical Co., Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.19.5 Chengdu Brilliant Pharmaceutical Co., Ltd. Key News & Latest Developments
7.20 Guangdong Eashu Pharmaceutical Co.,Ltd.
7.20.1 Guangdong Eashu Pharmaceutical Co.,Ltd. Company Summary
7.20.2 Guangdong Eashu Pharmaceutical Co.,Ltd. Business Overview
7.20.3 Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Major Product Offerings
7.20.4 Guangdong Eashu Pharmaceutical Co.,Ltd. Benign Prostatic Hyperplasia Drugs Revenue in Global Market (2018-2023)
7.20.5 Guangdong Eashu Pharmaceutical Co.,Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
